All In Biotech

Drug Trial Radar · NCT01014936

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor MSC2156119J Under Three Different Regimens in Subjects With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Aug 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

149

Actual

Start

Nov 30, 2009

Primary completion

Oct 31, 2015

Study completion Oct 31, 2015

Sponsor

Lead sponsor
EMD SeronoIndustry
Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Nov 17, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a an open-label, dose-escalation, first-in-man (FIM) study designed to explore MSC2156119J, in subjects with advanced solid tumors who have not responded to previous therapies or for whom no other therapies are available. Subjects will be assigned one of the dosing regimens: * Regimen 1: MSC2156119J once daily for 14 days, followed by 7 days with no treatment (21-day cycle) * Regimen 2: MSC2156119J three times per week (e.g., Days 1, 3, and 5) for three weeks (21-day cycle) * Regimen 3: MSC2156119J every day for three weeks (21-day cycle)

Conditions

  • Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available

Interventions

  • MSC2156119JDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Any Dose Limiting Toxicity (DLT)Time frame: Day 1, 3, 8, 14, 17 of Cycle 1 (for Regimen 1 and 3); Day 1, 3, 8, 15, 19 of Cycle 1 (for Regimen 2)
  2. Recommended Phase 2 Dose (RP2D)Time frame: Cycle 1 (Day 1 to Day 21)
  3. Number of Subjects With Treatment-Related Adverse EventsTime frame: Baseline up to 158.01 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • M.D. Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.